NGM-313

N/A

Report date: 2022/05/30 10:38:04

Base Information

Drug NameNGM-313
Drug Alias NameNGM-313MK-3655
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionKlotho beta agonistsFibroblast growth factor receptor 1 agonists
TargetsKlotho betaFibroblast growth factor receptor 1
Therapy Area/IndicationsObesityHepatitisMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[26] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNGM Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiotechnologines Farmacijos CentrasBiotechpharma UabWerthenstein Biopharma Gmbh +[6] 
Inactive CompaniesNGM Biopharmaceuticals IncMerck Sharp & Dohme LLC
Active IndicationsObesityHepatitisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A